BPTH - Bio-Path Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0700
+0.0300 (+1.47%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.0400
Open2.0415
Bid0.65 x 800
Ask2.73 x 1200
Day's Range2.0100 - 2.2001
52 Week Range1.6100 - 61.8000
Volume167,028
Avg. Volume291,671
Market Cap3.639M
Beta (3Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)-15.70
Earnings DateMar 14, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • ACCESSWIRE26 days ago

    Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

    DALLAS, TX / ACCESSWIRE / January 24, 2019 / Bio-Path Holdings, Inc. (NASDAQ: BPTH): The full report can be accessed by clicking on the following link: http://stonegateinc.com/reports/BPTH%20Update%20JAN%202019%20Final%20v3.pdf ...

  • GlobeNewswire27 days ago

    Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market

    Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes. The shares of common stock offered in the registered direct offering (but not the warrants or the shares of common stock underlying the warrants) were offered and sold by Bio-Path pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-215205), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (SEC) on January 9, 2017.  The offering of the shares of common stock was made only by means of a prospectus supplement that forms a part of the registration statement.

  • GlobeNewswirelast month

    Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market

    The warrants will have an exercise price of $2.65 per share and exercise period commencing immediately upon issuance and a term of five and one-half (5.5) years. Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes.

  • GlobeNewswirelast month

    Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

    As a result of the reverse stock split, every 20 shares of common stock issued and outstanding were consolidated into one issued and outstanding share.  The reverse stock split reduced the Company’s issued and outstanding shares of common stock from approximately 22.2 million to approximately 1.1 million. In addition, proportionate adjustments will be made to the exercise prices of the Company's outstanding stock options and warrants and to the number of shares issued and issuable under the Company's existing stock incentive plans.

  • GlobeNewswirelast month

    Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock

    Bio-Path Holdings, Inc., (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing and funding of its previously announced underwritten public offering of 8,592,308 shares of its common stock at a price to the public of $0.13 per share. Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes. A shelf registration statement on Form S-3 (Registration No. 333-215205) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (“SEC”) and was declared effective on January 9, 2017.

  • Benzingalast month

    The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...

  • GlobeNewswirelast month

    Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock

    Bio-Path Holdings, Inc., (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the pricing of an underwritten public offering of 8,592,308 shares of its common stock at a price to the public of $0.13 per share. Bio-Path expects to receive aggregate gross proceeds of approximately $1.1 million from the offering. The offering is expected to close on or about January 17, 2019, subject to the satisfaction of customary closing conditions.

  • GlobeNewswirelast month

    Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

    Bio-Path Holdings, Inc., (BPTH) (Bio-Path),  a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

  • GlobeNewswire2 months ago

    Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update from several clinical development programs and a 2019 business overview. “Over the last year, we made solid progress across our growing development pipeline, highlighted by positive interim data from our Phase 2 study of prexigebersen in de novo acute myeloid leukemia (AML) patients,” stated Peter H. Nielsen, chief executive officer of Bio-Path Holdings.

  • Could Bio-Path Holdings, Inc.’s (NASDAQ:BPTH) Investor Composition Influence The Stock Price?
    Simply Wall St.2 months ago

    Could Bio-Path Holdings, Inc.’s (NASDAQ:BPTH) Investor Composition Influence The Stock Price?

    Every investor in Bio-Path Holdings, Inc. (NASDAQ:BPTH) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • GlobeNewswire3 months ago

    Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that previously announced interim data from the Company’s Phase 2 study evaluating prexigebersen as a treatment for acute myeloid leukemia (AML) were presented in a poster at the 2018 American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 1-4, 2018 in San Diego, CA. Prexigebersen was safely administered to patients with untreated AML, who were considered unsuitable for standard chemotherapy.

  • Benzinga3 months ago

    The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

    Notwithstanding the scanty news flow, biotech stocks came under intense selling pressure last week, pushing the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) further into the red. Here's a list of ...

  • Associated Press3 months ago

    Bio-Path: 3Q Earnings Snapshot

    On a per-share basis, the Bellaire, Texas-based company said it had a loss of 27 cents. The company's shares closed at 44 cents. A year ago, they were trading at $2.97. _____ This story was generated by ...

  • Simply Wall St.4 months ago

    What does Bio-Path Holdings Inc’s (NASDAQ:BPTH) Balance Sheet Tell Us About Its Future?

    The direct benefit for Bio-Path Holdings Inc (NASDAQ:BPTH), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...

  • Associated Press6 months ago

    Bio-Path: 2Q Earnings Snapshot

    The Bellaire, Texas-based company said it had a loss of 15 cents per share. The company's shares closed at $1.41. A year ago, they were trading at $3. _____ This story was generated by Automated Insights ...

  • ACCESSWIRE6 months ago

    Bio-Path Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 15, 2018 / Bio-Path Holdings, Inc. (NASDAQ: BPTH ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 15, 2018 at 8:30 AM Eastern ...